Lilly freezes pay for workers, executives

Back to TopCommentsE-mailPrintBookmark and Share

Eli Lilly and Co. will freeze pay this year for most workers, including executives, a spokesman said Wednesday.

The pay freeze will save $400 million through 2016, said Ed Sagebiel, a spokesman for the Indianapolis-based company. Lilly won’t give pay raises to executives, supervisors or most workers. Some bonuses will also be reduced. The company had 38,350 workers in 2012, according to data compiled by Bloomberg.

The drugmaker is reducing expenses and counting on experimental Alzheimer’s and diabetes drugs to revive growth as it loses revenue from top products to generic competitors. Cymbalta, a depression pill that at $5 billion a year is the drugmaker’s biggest seller, loses patent protection in December. Zyprexa, an anti-psychotic, had peak sales of $5.03 billion in 2010, the year before it lost patent protection.

“This is a difficult, but necessary decision,” Sagebiel said in an e-mail. “While we remain confident in our future, we continue to face the most significant challenges in our history.

Lilly expects a 20-percent reduction in revenue in 2014 because of the expiration of the Cymbalta and Evista patents in the U.S., he said. Evista, used in the treatment of osteoporosis as well as breast cancer, loses protection next year. It generated more than $1 billion in 2012.

‘‘This action is necessary to withstand the impact of upcoming patent expirations and to support the launch of our large phase III pipeline,’’ CEO John Lechleiter, 59, said in a letter to employees Wednesday, a copy of which was obtained by Bloomberg. ‘‘The current situation requires us to take the appropriate action now to secure our company’s future. We can’t allow ourselves to let up and fail to make the tough choices.”

Lechleiter hasn’t received a pay raise since 2010, according to data compiled by Bloomberg.

The company is scheduled to report second-quarter earnings on July 24.

Lilly shares fell less than 1 percent Wednesday, to $50.67 each, at the close of trading. The company has gained 2.7 percent this year, compared with a 21-percent increase in the Standard & Poor’s 500 Pharmaceuticals Index of 13 drugmakers.


  • desparate times.
    Looks like its "bet the farm" time for Lilly: http://pipeline.corante.com/archives/2013/07/12/lilly_goes_all_in_on_solanezumab.php
  • Failed policies
    Lilly has been plagued by bad management at the Director level, middle management and more. Their pipeline is a joke compared to other Pharmas . Time for a shake up of management
  • Tough for lower paid
    Larry, agree it is not the $100+ that are the big issue, I am sure there are 20,000 people who earn less than $60,000 that count on those raises if they are doing a great job. I am sure the benefits at LLY are still worth it to stay around. This "austerity" will be a hit to our area. As LLY tightens their belt, their employees will tighten theirs and push off pushes they might have otherwise made. The fact that Lechleiter with a base salary of $1.5MM, hasn't had an increase since 2010 is not comforting to his teammate in the warehouse who pulls down $40,000.
  • hold the line
    Most people in central Indiana will have a hard time sympathizing with people who are "frozen" at $100k or $200k. Employees are hired at a certain rate. There should be no reason for automatic pay raises. There also should be no reason for the constant inflation of prices for goods and services.

Post a comment to this story

We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
You are legally responsible for what you post and your anonymity is not guaranteed.
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
thisissue1-092914.jpg 092914

Subscribe to IBJ